1-17 of 17
Chau Dang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO1-06-03: Efficacy of First-line Treatments for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer: A Systematic Literature Review and Network Meta-analysis Feasibility Assessment

Priyanka Sharma, Chau Dang, Christopher Drudge, Amrita Debnath, Manvir Rai, Eric Gauthier, Edward Broughton
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO1-06-03.
https://doi.org/10.1158/1538-7445.SABCS23-PO1-06-03
Published: 02 May 2024
View article titled, Abstract PO1-06-03: Efficacy of First-line Treatments for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer: A Systematic Literature Review and Network Meta-analysis Feasibility Assessment
Journal Articles

Abstract PS11-02: Clinical risk factors of Central Nervous System (CNS)-related death in patients with HER2-positive metastatic breast cancer

Emanuela Ferraro, Rabih Bou Nassif, Anne Reiner, Samantha Brown, Umberto Tosi, Katherine Panageas, Chau Dang, Andrew D Seidman, Nelson Moss
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS11-02.
https://doi.org/10.1158/1538-7445.SABCS23-PS11-02
Published: 02 May 2024
View article titled, Abstract PS11-02: Clinical risk factors of Central Nervous System (CNS)-related death in patients with HER2-positive metastatic breast cancer
Journal Articles

Abstract RF02-06: AVIATOR/TBCRC045: A randomized phase II study of vinorelbine (N) + trastuzumab (H) alone or combined with avelumab (A) +/- utomilumab (U) in patients (pts) with HER2+ metastatic breast cancer (MBC) (NCT03414658)

Adrienne Waks, Ruichao Shi, Meredith Regan, Chau Dang, Cesar Santa-Maria, Kelly Westbrook, Vandana Abramson, Rashmi Murthy, Rita Nanda, Hope Rugo, Amy Clark, Candace Mainor, Claire Dees, Valentina Hoyos, Kathy Miller, Erica Stringer-Reasor, Natasha Hunter, Sun Young Oh, Michelle DeMeo, Amanda Okpoebo, Erin Elias, Busem Kurt, Nancy Lin, Mothaffar Rimawi, Antonio Wolff, Elizabeth Mittendorf, Shom Goel, Sara Tolaney, Sherene Loi, Ian Krop
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): RF02-06.
https://doi.org/10.1158/1538-7445.SABCS23-RF02-06
Published: 02 May 2024
View article titled, Abstract RF02-06: AVIATOR/TBCRC045: A randomized phase II study of vinorelbine (N) + trastuzumab (H) alone or combined with avelumab (A) +/- utomilumab (U) in patients (pts) with HER2+ metastatic breast cancer (MBC) (NCT03414658)
Journal Articles

Abstract PO3-04-07: Characterization of response to first-line chemotherapy, trastuzumab, and pertuzumab among patients with de novo metastatic HER2-positive breast cancer

Emanuela Ferraro, Atif Khan, George Plitas, Yuan Chen, Mehnaj Ahmed, Julia An, Chau Dang, Mark Robson, Sarat Chandarlapaty, Shanu Modi, Pedram Razavi, Sherry Shen
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-04-07.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-04-07
Published: 02 May 2024
View article titled, Abstract PO3-04-07: Characterization of response to first-line chemotherapy, trastuzumab, and pertuzumab among patients with de novo metastatic HER2-positive breast cancer
Journal Articles

Abstract PO2-20-01: The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+ Metastatic Breast Cancer (TBCRC 062)

Heather Parsons, Kathryn Ruddy, Stefania Morganti, Karen Smith, Victoria Attaya, Eliza Kallfelz, Michelle DeMeo, Jamie LaScala, Shirley Mertz, Teri Pollastro, Patricia Spears, Adam Brufsky, Chau Dang, Susan Dent, Ahmed Elkhanany, WIlliam Gwin, Ciara O'Sullivan, Kathy Miller, Sara Nunnery, Elaine Walsh, Anna Maria Storniolo, Sara Tolaney, Nabihah Tayob, Antonio Wolff, Eric Winer, Mothaffar Rimawi, Ian Krop, Nancy Lin
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-20-01.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-20-01
Published: 02 May 2024
View article titled, Abstract PO2-20-01: The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+ Metastatic Breast Cancer (TBCRC 062)
Journal Articles

Abstract PO2-12-07: Risk of anaphylaxis associated with the use of pertuzumab or other biologics with potential for use outside the hospital

Thibaut Sanglier, Tom Chambers, Joanna Harton, Laurentia Wahyudi, Magali Genevray, Eleonora Restuccia, Cécile Droz-Perroteau, Chau Dang
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-12-07.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-12-07
Published: 02 May 2024
View article titled, Abstract PO2-12-07: Risk of anaphylaxis associated with the use of pertuzumab or other biologics with potential for use outside the hospital
Journal Articles

Abstract 3412: Benralizumab for treatment of eosinophil-related cutaneous adverse events associated with checkpoint inhibitors and anticancer targeted therapies: Phase 2 study

Mario E. Lacouture, Tara Maier, Alexander Pan, Anna Chen, George Dranitsaris, Neil J. Shah, Sarat Chandarlapaty, Chau Dang, Devika Gajria, Allison Gordon, Neil Iyengar, Pedram Razavi, Mark Robson, Ezra Rosen, Serena Wong, Ucalene Harris, Kwami Ketosugbo, Cindy Bravo, Manu Jain, Alina Markova
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3412.
https://doi.org/10.1158/1538-7445.AM2024-3412
Published: 22 March 2024
View article titled, Abstract 3412: Benralizumab for treatment of eosinophil-related cutaneous adverse events associated with checkpoint inhibitors and anticancer targeted therapies: Phase 2 study
Journal Articles

Abstract P1-08-02: Cytochrome P450 reductase gene, POR, associated with paclitaxel induced peripheral neuropathy in patients of European ancestry from the adjuvant breast cancer trial, ECOG-ACRIN E5103

Fei Shen, Guanglong Jiang, Laura Gardner, Gloria Xue, Santosh Philips, Reynold Ly, Osei Wilberforce, Xi Wu, Erica Cantor, Chau Dang, Donald Northfelt, Todd Skaar, Kathy D. Miller, George Sledge, Bryan P Schneider
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-08-02.
https://doi.org/10.1158/1538-7445.SABCS21-P1-08-02
Published: 15 February 2022
View article titled, Abstract P1-08-02: Cytochrome P450 reductase gene<em>, POR,</em> associated with paclitaxel induced peripheral neuropathy in patients of European ancestry from the adjuvant breast cancer trial, ECOG-ACRIN E5103
Journal Articles

Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)

Sara M Tolaney, Lorenzo Trippa, William Barry, Jiani Hu, Chau Dang, Denise Yardley, Steven Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Douglas Weckstein, Antonio Wolff, Katherine Reeder-Hayes, Hope Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Merrill Garrett, Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel Jankowitz, Michelle Demeo, Ann Partridge, Harold Burstein, Eric P. Winer, Ian Krop
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): GS1-05.
https://doi.org/10.1158/1538-7445.SABCS19-GS1-05
Published: 15 February 2020
View article titled, Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)
Journal Articles

Abstract P1-18-01: Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: A retrospective exploratory analysis

Sandra M Swain, Harrison Macharia, Javier Cortes, Chau Dang, Luca Gianni, Sara Hurvitz, Christian Jackisch, Andreas Schneeweiss, Dennis Slamon, Pinuccia Valagussa, Yolande du Toit, Dominik Heinzmann, Adam Knott, Chunyan Song, Patricia Cortazar
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P1-18-01.
https://doi.org/10.1158/1538-7445.SABCS19-P1-18-01
Published: 15 February 2020
View article titled, Abstract P1-18-01: Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: A retrospective exploratory analysis
Journal Articles

Abstract P2-10-01: The genomic landscape of breast cancer in African American women

Cristian Serna-Tamayo, Joshua Z Drago, Carlos Dos Anjos, Joshua Herbert, Fresia Pareja, Shanu Modi, Komal Jhaveri, Chau Dang, David B Solit, Larry Norton, Mauricio Scaltriti, Jorge S Reis-Filho, Sarat Chandarlapaty, Mark E. Robson, Pedram Razavi
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P2-10-01.
https://doi.org/10.1158/1538-7445.SABCS19-P2-10-01
Published: 15 February 2020
View article titled, Abstract P2-10-01: The genomic landscape of breast cancer in African American women
Journal Articles

Abstract PD10-02: Patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel + trastuzumab (TH) (ATEMPT) trial (TBCRC 033)

Ann Partridge, Yue Zheng, Shoshana Rosenberg, Richard Gelber, Shari Gelber, William Barry, Chau Dang, Denise Yardley, Steven Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Douglas Weckstein, Antonio Wolff, Katherine Reeder-Hayes, Hope Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Merrill Garrett, P. Kelly Marcom, Kathy Albain, Patricia Defusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel Jankowitz, Michelle DeMeo, Harold Burstein, Eric P. Winer, Ian Krop, Sara Tolaney
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): PD10-02.
https://doi.org/10.1158/1538-7445.SABCS19-PD10-02
Published: 15 February 2020
View article titled, Abstract PD10-02: Patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel + trastuzumab (TH) (ATEMPT) trial (TBCRC 033)
Journal Articles

Abstract P2-16-10: Disease free survival rate with dose dense Doxorubicin and Cyclophosphamide followed by weekly Paclitaxel with Trastuzumab and Pertuzumab (ddACTHP) in patients with HER2-positive early stage breast cancer: A single institution experience

Jasmeet C Singh, Sujata Patil, Larry Norton, Mark Robson, Chau Dang
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P2-16-10.
https://doi.org/10.1158/1538-7445.SABCS19-P2-16-10
Published: 15 February 2020
View article titled, Abstract P2-16-10: Disease free survival rate with dose dense Doxorubicin and Cyclophosphamide followed by weekly Paclitaxel with Trastuzumab and Pertuzumab (ddACTHP) in patients with HER2-positive early stage breast cancer: A single institution experience
Journal Articles

Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies

Lee W. Jones, Marilyn L. Kwan, Erin Weltzien, Sarat Chandarlapaty, Barbara Sternfeld, Carol Sweeney, Philip S. Bernard, Adrienne Castillo, Laurel A. Habel, Candyce H. Kroenke, Bryan M. Langholz, Charles P. Queensberry, Jr, Chau Dang, Britta Weigelt, Lawrence H. Kushi, Bette J. Caan
Journal: Cancer Research
Cancer Res (2016) 76 (18): 5415–5422.
https://doi.org/10.1158/0008-5472.CAN-15-3307
Published: 15 September 2016
View article titled, Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies
Open the PDF for Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies in another window
Includes: Supplementary data
Journal Articles

Abstract CT330: Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Payal D. Shah, Mary E. Moynahan, Shanu Modi, Nicola Hamilton, Betty Ann Caravella, Stephen Zamora, Chau Dang, Theresa Gilewski, Tiffany Traina, Elizabeth Comen, Steven M. Sugarman, Gabriella D'Andrea, Diana Lake, Shari Goldfarb, Sujata Patil, Anne Covey, Michael Berger, Mario Lacouture, Larry Norton, Clifford A. Hudis, Jose Baselga, Sarat Chandarlapaty, Maura Dickler
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): CT330.
https://doi.org/10.1158/1538-7445.AM2015-CT330
Published: 01 August 2015
View article titled, Abstract CT330: Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Journal Articles

Abstract OT3-1-01: A two-cohort, phase II, cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive, locally advanced, inflammatory, or early breast cancer

Sandra M Swain, Michael S Ewer, Hannah Douthwaite, Tania Szado, Maeve Waldron-Lynch, Chau Dang
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): OT3-1-01.
https://doi.org/10.1158/1538-7445.SABCS14-OT3-1-01
Published: 01 May 2015
View article titled, Abstract OT3-1-01: A two-cohort, phase II, cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive, locally advanced, inflammatory, or early breast cancer
Journal Articles

Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

Katherine A Hoadley, William T Barry, Brandelyn N Pitcher, Joel S Parker, Matthew D Wilkerson, William Irvin, Jr, Norah Lynn Henry, Sara M Tolaney, Chau Dang, Ian E Krop, Donald A Berry, Elaine R Mardis, Charles M Perou, Eric P Winer, Clifford A Hudis, Lisa A Carey
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): S3-06.
https://doi.org/10.1158/1538-7445.SABCS14-S3-06
Published: 01 May 2015
View article titled, Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer